largely unknown. Understanding the mechanisms responsible for increasing lymphangiogenesis in ARLs should provide new targets for therapeutic intervention to block tumor growth and metastasis.
To date, the molecular studies performed on ARL tissues have shown that HIV-1 is not inserted within malignant cells. This suggests that HIV-1 may contribute to the incidence of ARL through indirect mechanisms, which may rely on action of HIV-1 proteins expressed in lymphatic tissue rather than being a direct effect of the virus itself. 11 The HIV-1 matrix protein p17 (p17) is a 17-kDa myristoylated protein derived from the extreme N-terminal region of the Gag precursor protein p55. It is a key component of the HIV-1 preintegration complex and performs crucial functions throughout the HIV-1 life cycle. 12 P17 is continuously released in the extracellular space from HIV-1-infected cells, and it is detected in the plasma of HIV-1-infected patients and in tissue specimens. 13, 14 This structural viral protein accumulates and persists in the lymph nodes of patients under HAART in the absence of any HIV-1 replicative activity. 14 Indeed, amounts of the HIV-1 protein did not noticeably differ in lymph nodes specimens either before initiation of HAART or during treatment where the virus burden was significantly decreased.
Extracellularly, p17 has been found to deregulate the biological activity of many different immune cells. [15] [16] [17] [18] Experiments performed on human primary monocytes have shown that p17 exerts a chemokine-like activity. This activity was mediated by p17 binding to chemokine (C-X-C motif) receptor-1 (CXCR1), and the viral protein was found to mimic some of the interleukin-8 (IL-8) biological activities. 19 More recently, p17 was found to bind with high affinity to chemokine (C-X-C motif) receptor-2 (CXCR2), a CXCR1-related cellular receptor known to predominantly mediate angiogenesis. 20 p17 was found to promote angiogenesis by interacting with both CXCR1 and CXCR2 expressed on the endothelial cell (EC) surface and activating a protein kinase B (Akt)-dependent extracellular signal-regulated kinase (ERK) signaling pathway. 21 Recently, Mu et al 22 showed the expression of CXCR1 and CXCR2 on the surface of human dermal-derived lymphatic ECs (LECs) and provided evidence that IL-8 is involved in lymphangiogenesis, highlighting a completely new route for promoting the complex process leading to new lymphatic vessel formation. In light of this finding, the present study was aimed to determine the effect of p17 on human LEC lymphangiogenesis and to elucidate the mechanism underlying the activity of the viral protein.
Herein, we report that primary human lymph node-derived LECs (LN-LECs) are positive for CXCR1 and CXCR2 expression. We demonstrate that both CXCR1 and CXCR2 are responsible for p17 lymphangiogenic activity on LN-LECs. Our results also reveal that p17-induced lymphangiogenesis is mediated, in part, by the endothelin-1 (ET-1)/ET-1 B receptor (ET B R) axis. Finally, we provide in vivo evidence on the capability of p17 to induce lymphangiogenesis directly.
Materials and Methods
Materials and Methods are available in the online-only Supplement.
Results

CXCR1 and CXCR2 Are Expressed on Human Primary LN-LECs
To explore the presence of CXCR1 and CXCR2 on the surface of LN-LECs, we examined the expression of both receptors in cultured LN-LECs under confocal imaging. CXCR1 and CXCR2 are expressed on the surface of LN-LECs as shown by immunofluorescence on fixed nonpermeabilized cells using mAbs to CXCR1 and CXCR2 as specific reagents ( Figure 1A ). Immunofluorescence showed a higher intensity for CXCR1 than for CXCR2, suggesting CXCR1 to be more highly expressed than CXCR2 on the surface of LN-LECs. Whereas CXCR2 signals on the cell surface defined a punctate pattern evenly distributed over the entire plasma membrane, the distribution of CXCR1 on the surface of LN-LEC appeared as larger circular patterns concentrated on distinct membrane areas or structures ( Figure 1A ). This distribution was not maintained when cells were permeabilized or when the receptor was engaged by CXCR1 mAb before cells were fixed but not permeabilized. This finding suggests a CXCR1 cell surface distribution at plasma membrane structures or domains that are not stable and hence, not preserved to be detected by antibodies unless conserved directly by fixation of live, nonpermeabilized cells. These structures do not seem to be supported by the actin cytoskeleton: immunofluorescence using actin-binding fluorescently conjugated phalloidin did not show any colocalization with CXCR1 ( Figure 1B ). The expression of CXCR1 and CXCR2 was then studied both at the protein and at the transcriptional level. As shown in Figure I in the online-only Data Supplement, both receptors were detected by Western blot in the total protein extract obtained from LN-LECs. Although CXCR1 was found to be more highly expressed than CXCR2, the difference was not statistically significant. Similar results were obtained by real-time polymerase chain reaction.
P17 Requires Both CXCR1 and CXCR2 to Induce Capillary-Like Structures
CXCR1 and CXCR2 are involved in p17-induced angiogenesis. 21 investigated the capability of p17 to promote capillary-like structure formation in vitro. To minimize the physiological lymphangiogenic activity of LN-LECs, low passage cells were nutrient starved for 24 hours before harvesting. Cells were then seeded on 48-well plates (5×10 4 per well) containing polymerized plugs of growth factor-reduced basement membrane extract (Cultrex). As shown in Figure II in the online-only Data Supplement, starved LN-LECs seeded on Cultrex and cultured ≤8 hours formed a cellular monolayer. In the presence of p17, LN-LECs formed a consistent network of capillary-like structures. Dose-response experiments showed that p17 exerted its lymphangiogenic activity at a concentration as low as 5 ng/mL, reaching a peak of lymphangiogenic potency at a protein concentration of 10 ng/mL. Parallel experiments showed that the lymphangiogenic activity of p17 was similar to that exerted by VEGF-C and IL-8, whereas the irrelevant protein glutatione S-transferase did not induce any capillary-like structure formation ( Figure II in the online-only Data Supplement). The activity of p17 was blocked by preincubating the medium containing p17 (10 ng/mL) with the p17 neutralizing mAb MBS-3 15 (1 μg/mL), whereas incubation with irrelevant control mAb (1 μg/mL) had no effect, thus confirming the specificity of the p17 effect ( Figure 2A ). Because the angiogenic response of ECs requires coordinated cytoskeletal rearrangement mediated by CXCR1 and CXCR2 and both receptors are required for angiogenic activity of p17 and IL-8, 21 we determined the involvement of both receptors in p17-mediated capillary-like structure formation by examining the effect exerted by neutralizing mAbs to CXCR1 and CXCR2. As shown in Figure 2B , after 8 hours of culture, LN-LECs formed capillary-like structures in medium containing p17 or p17 plus the isotype-matched mAb. The neutralizing mAb to CXCR1 was strongly inhibitory (63.1±3.6%) toward p17-induced capillary-like structure formation, whereas mAb to CXCR2 accounted for a smaller 21.6±4.2% decrease. Blocking of both receptors by using a combination of the 2 mAbs resulted in an almost complete inhibition (83.8±2.7%) of p17-induced capillary-like structure formation. Our data demonstrate that both CXCR1 and CXCR2 are involved in p17-induced capillary-like structure formation and most likely cooperate in promoting lymphangiogenesis, with a major role for CXCR1 in mediating the p17 lymphangiogenic activity. This finding was confirmed by a knockdown approach based on small interfering RNA (siRNA). As shown in Figure III Supplement). These data support a major role for CXCR1 in the p17-driven lymphangiogenic process.
P17-Induced Capillary-Like Structure Formation Requires Activation of the Akt-Dependent ERK Signaling Pathway
ERK signaling via Akt was defined as the pathway responsible for p17-induced angiogenesis. 21 Phosphatidylinositol 3-kinase (PI3K) activity was identified as a key intermediate in coupling CXCR1 and CXCR2 to ERK1/2 and Akt phosphorylation, a key event for triggering EC angiogenic functions. 20 These data prompted us to investigate the ability of p17 to induce Akt and ERK1/2 phosphorylation in LN-LECs. As shown in Figure 3A , p17 markedly stimulated the phosphorylation of both Akt and ERK1/2. This occurred through the interaction of p17 with CXCR1 and CXCR2 ( Figure IV in the online-only Data Supplement). Phosphorylation was transient for pAkt because it reached a peak at 30 minutes and declined after 1 hour of p17 stimulation. As expected, the irrelevant protein glutatione S-transferase did not induce any Akt and ERK1/2 activation.
To investigate further whether these pathways play a role in p17-induced capillary-like structure formation and to characterize the intracellular signaling mechanisms, LN-LECs were incubated for 8 hours with p17 and optimal concentration of the inhibitors of PI3K (LY294002 [10 μmol/L] and wortmannin [100 nmol/L]), mitogen-activated protein kinase kinase [MEK]/ERK1/2 (PD98059 [10 μmol/L]), and Akt (Akt inhibitor VIII [1 μmol/L]). As shown in Figure 3B , capillarylike structure formation in p17-stimulated LN-LECs was significantly inhibited by LY294002, wortmannin, PD98059, and Akt inhibitor VIII. Our results suggest that similarly to what was observed in human umbilical vein ECs, the PI3K/Akt and MEK/ERK1/2 pathways are both required and critical for production and maintenance of p17-induced LN-LEC-derived capillary-like networks on growth factor-reduced basement membrane extract.
P17 Induces Formation of Sprouts From LN-LEC Spheroids
The entrapment of EC spheroids in biopolymeric gels represents a 3-dimensional (3D) cell model that was found to be an attractive potential method of forming a microvascular network that mimics in vivo sprouting angiogenesis. 23 The 3D organotypic culture is based on the property of LECs to form spheroids under nonadherent conditions, and it has proven useful for studies on endothelial capillary sprouting. Modifying the recently established LEC spheroid differentiation model, 24 we developed a spheroidal system of LN-LECs aimed at mimicking the correct 3D assembly of the normal lymphatic vessel wall. LN-LEC-derived spheroids were treated with p17, and a 3D organotypic culture was performed under nonadherent conditions. As shown in Figure V in the online-only Data Supplement, p17 induced a dramatic outgrowth of sprouts in LN-LEC spheroids in 24 hours. The number of sprouts obtained in p17-treated LN-LEC spheroids was superimposable to that obtained in the same period of time with a molecule known to promote lymphangiogenesis (IL-8). On the contrary, minimal sprouting was observed in control LN-LECs and in LN-LECs treated for 24 hours with the irrelevant protein glutatione S-transferase. These data strongly suggest that also in the 3D environment p17 displays potent lymphangiogenic activity, which is comparable to that induced by IL-8.
P17 Stimulates LN-LEC Migration
Capillary-like formation and sprout formation from spheroids are in vitro assays that involve ECs present at different levels of confluency and are indicative of 2 different angiogenic functions, migration, and morphogenesis. To investigate the effect of p17 on LN-LECs migratory activity, further studies were performed using the wound healing assay. This method allows us to investigate the ability of viral protein to modulate cell migration by sealing a confluent cell monolayer after a mechanical injury. LN-LECs were grown on collagen-coated plates and starved for 24 hours. Confluent monolayers were scratched with a 200-μL tip, and the percentage of wound healing was observed during a period of 12 hours. As shown in Figure VIA in the online-only Data Supplement, control, as well as glutatione S-transferase-treated, LN-LECs reached ≈35% healing (range from 28% to 44%) only after 12 hours of culture, whereas at the same time LN-LECs treated with p17 reached 100% healing, showing a considerable improvement in scrape wound repair ability. To determine the involvement of CXCR1 and CXCR2 in p17-induced LN-LEC migration, immediately after scratching, cell monolayers were cultured for 12 hours with or without p17 (10 ng/mL) in the presence or absence of a neutralizing mAb to CXCR1, CXCR2 (2.5 μg/mL), or a control isotype-matched mAb (2.5 μg/mL). LN-LECs reached 100% of wound healing after 12 hours of culture in the presence of p17 or p17 plus the isotype-matched mAb. The neutralizing mAb to CXCR1 was strongly inhibitory (range from 77.2% to 88.8%), whereas the neutralizing mAb to CXCR2 accounted for a more modest decrease (range from 18.7% to 22.3%) of p17 activity ( Figure VIB in the online-only Data Supplement).
ET-1 Is Selectively Released by LN-LECs On p17 Stimulation
To understand whether the lymphangiogenic activity of p17 was direct or, at least in part, mediated by other lymphangiogenic molecules, we performed analysis of p17-stimulated LN-LEC secretome by using a human angiogenesis array. As shown in Figure 4A , after 6 hours of culture, LN-LECs did not spontaneously release any of the tested molecules, including VEGF and VEGF-C, with the only exceptions being Serpin E1 and low levels of ET-1. At the same time, p17 (10 ng/mL) was found to trigger the secretion of ET-1 powerfully, whereas it proved unable to induce secretion of any other proangiogenic/lymphangiogenic factors tested, with the exception of low levels of pentraxin 3, monocyte chemotactic protein-1, tissue inhibitor of metalloproteinase-1, and thrombospondin-1, which were detected in the supernatant of p17-treated LN-LECs.
To confirm the capability of p17 to promote ET-1 release by LN-LECs, a kinetic study was performed by collecting the supernatant of p17-treated or p17-untreated cells at 1, 3, and 6 A, Supernatants of LN-LECs with or without treatment for 6 hours at 37°C with p17 (10 ng/mL) were evaluated for the presence of proangiogenic/lymphangiogenic molecules by a human proteome array. The results are expressed as relative mean values of duplicates given as OD/mm 2 . B, LN-LECs were treated with p17 at a concentration of 10 and 100 ng/mL. Culture supernatants were collected at 1, 3, and 6 hours after the beginning of stimulation. C, LN-LECs were incubated for 6 hours with p17 (10 ng/mL) in the presence or in the absence of phosphatidylinositol 3-kinase inhibitors (LY294002 [10 μmol/L] or wortmannin [WT; 100 nmol/L]), the mitogen-activated protein kinase kinase (MEK)/extracellular signal-regulated kinase (ERK) 1/2 inhibitor PD98059 (10 μmol/L), or the Akt inhibitor VIII (1 μmol/L). Culture supernatants were collected at 6 hours after the beginning of stimulation. D, LN-LECs were treated with p17 at a concentration of 10 and 100 ng/mL (except negative controls) in the presence or in the absence of monensin (10 μmol/L). Culture supernatants were collected at 1, 3, and 6 hours after the beginning of stimulation. Culture supernatants were analyzed for the presence of endothelin-1 (ET-1) by a standard quantitative ELISA. Bars represent the mean±SD of triplicate samples. Statistical analysis was performed by 1-way ANOVA (C) and by 1-way ANOVA performed separately for each concentration of p17 across the 3 groups (B and D). Bonferroni post test was used to compare data (*P<0.05, **P<0.01, ***P<0.001). ADAMTS-1 indicates a disintegrin and metalloproteinase with a thrombospondin type 1 motif; CTR, control; EGF, epidermal growth factor; FGF, fibroblast growth factor; IL-8, interleukin-8; LAP (TGF-β1), transforming growth factor beta 1; MCP, monocyte chemotactic protein; NT, not treated cells; PD-ECGF, platelet-derived endothelial cell growth factor; PDGF-AA, platelet derived growth factor-AA; TGF, transforming growth factor; TIMP, tissue inhibitor of metalloproteinase; and VEGF, vascular endothelial growth factor. hours after stimulation. As shown in Figure 4B , p17 induced a significant increase of ET-1 release at all tested times. The effect on ET-1 secretion by LN-LECs obtained using p17 at the concentration of 10 ng/mL did not differ from those obtained using a higher dose (100 ng/mL) of viral protein.
To investigate further whether PI3K/Akt and MEK/ERK1/2 signaling pathways play a role in p17-induced ET-1 secretion, LN-LECs were incubated for 6 hours with p17 and optimal concentrations of the inhibitors of PI3K (LY294002 [10 μmol/L] and wortmannin [100 nmol/L]), MEK/ERK1/2 (PD98059 [10 μmol/L]), and Akt (Akt inhibitor VIII [1 μmol/L]). As shown in Figure 4C , ET-1 secretion was significantly inhibited by LY294002, wortmannin, PD98059, and Akt inhibitor VIII. Our results suggest that the ET-1 secretion from LN-LECs is dependent on p17-induced activation of both PI3K/Akt and MEK/ERK1/2 pathways.
Increased level of ET-1 protein secretion induced by p17 treatment was not paralleled by an increase in specific ET-1 mRNA expression. When ET-1 messages were quantified by real-time polymerase chain reaction Taqman Assay in LN-LECs treated or not with p17 (10 ng/mL), we observed that ET-1 mRNA was expressed at constant levels, irrespective of p17 treatment ( Figure VII in the online-only Data Supplement).
ET-1 is accumulated into Weibel-Palade bodies, the most recognizable endothelial storage granule, 25 whose exocytosis is blocked by neutralization of the acidic intra-Weibel-Palade bodies pH by treatment with monensin. 26 Therefore, to evaluate if the increased amount of ET-1 present in the supernatant of p17-treated LN-LEC was because of the capability of p17 to induce secretion of ET-1, monensin was added to LN-LEC cultures. As shown in Figure 4D , treatment with monensin inhibited the release of ET-1 by p17-treated LN-LECs within 1 hour of incubation, whereas the percentage of inhibition increased with duration of exposure.
P17-Induced Capillary-Like Structure Formation Is Partially Mediated by the ET-1/ET B R Axis
We recently demonstrated that LECs express high levels of ET B R both in vitro and in vivo, whereas the ET-1A receptor is only barely expressed on these cells. 27 Moreover, we found that ET-1 exerts a potent lymphangiogenic activity by interacting with ET B R. 27 We investigated whether p17-induced capillarylike structure formation and migration were mediated by ET-1 by selectively blocking ET B R with specific ET B R antagonist BQ788. As shown in Figure 5A , p17-induced capillary-like structure formation was significantly inhibited in the presence of specific ET B R antagonist BQ788. The presence of BQ788 in medium during p17 stimulation accounted for a 61.2±5.2% inhibition of LN-LEC tube formation. No significant effect on p17 angiogenic activity was observed when LN-LECs were stimulated with p17 in the presence of specific ET-1A receptor antagonist BQ123. These findings suggest that p17 lymphangiogenic activity is strongly, but not entirely, supported by activation of the ET-1/ET B R axis. A strong involvement of ET-1/ET B R axis also in p17-induced LN-LEC migratory activity was demonstrated using the wound healing assay. As shown in Figure 5B , a pronounced impairment in wound repair occurred in p17-treated LN-LECs when cells were cultured in the presence of BQ788, whereas the presence of BQ123 did not affect p17-dependent cell migratory activity. Our results clearly demonstrate that ET-1 through ET B R cooperates with p17 in promoting and sustaining LN-LEC angiogenic and migratory activity. Values reported for LN-LEC capillary-like structure (tubes) formation are the mean±SD of 3 independent experiments. Statistical analysis was performed by 1-way ANOVA, and the Bonferroni post test was used to compare data (*** P<0.001). B, Confluent LN-LEC monolayers were scratched and cultured for 12 hours at 37°C with medium alone (NT) or containing p17 (10 ng/mL) alone or in combination with 0.65 μg/mL ET B R antagonist BQ788 or with 0.65 μg/mL ET-1A receptor (ET A R) antagonist BQ123. Images are representative of 3 independent experiments with similar results (magnification ×10). Values reported for LN-LEC capillary-like structure (tube) formation are the mean±SD of 3 independent experiments. Statistical analysis was performed by 1-way ANOVA, and the Bonferroni post test was used to compare data (***P<0.001).
P17 Promotes Lymphangiogenesis In Vivo
Because p17 stimulated lymphangiogenesis of LECs in vitro by promoting the secretion of ET-1 and possibly of other lymphangiogenic molecules, we investigated whether p17 may induce per se lymphangiogenesis in vivo. To this end, we implanted Matrigel containing p17, ET-1 (positive control), or PBS (negative control) into the dorsal subcutaneous tissue of C57BL/6 mice. 27 As shown in Figure 6 , immunostaining of Matrigel plugs with polyclonal Ab to lymphatic vessel endothelial receptor-1 identified pronounced lymphatic vessel formation in those containing p17 and ET-1 compared with Matrigel controls. Staining was confined within discrete areas at the boundaries with the surrounding murine tissue. The number of LECs recruited into the Matrigel plugs was quantified by flow cytometry. As shown in the Figure 6 graph, flow cytometric analysis revealed a consistent increase in the number of LECs (CD31 + /lymphatic vessel endothelial receptor-1 + ) recruited to Matrigel after p17 and ET-1 stimulation compared with the control cells. These results indicate that p17 acts as a lymphangiogenic factor via direct stimulatory effects on LN-LECs because its presence in Matrigel plugs is per se able to recruit LECs and promote the outgrowth of lymphatic vessels in vivo.
Discussion
IL-8 exerts a potent angiogenic and lymphangiogenic activity by interacting with CXCR1 and CXCR2. 21, 22 In previous studies, we showed that HIV-1 matrix protein p17 displays IL-8-like activities by binding to both IL-8 receptors. In particular, the viral protein was found to promote angiogenesis strongly in vitro and in vivo using the same IL-8 machinery. 21 In this study, we demonstrate that LN-LECs do express CXCR1 and CXCR2 and that p17 interaction with CXCR1 and CXCR2 is responsible for a potent activation of the lymphangiogenic process.
We previously showed that exogenous p17 is present in the serum of HIV-infected patients at nanomolar concentrations. 13 The viral protein was also detected in lymphoid organs, where it accumulates and persists for years even in patients undergoing successful HAART. 14 This finding, together with the more recent evidence that latently HIV-1-infected resting T-cells are capable of producing HIV-1 Gag without supporting spreading infection, 28 strengthens the possibility that p17 synthesis and release may occur even under HAART.
In this study, we show that p17 exerts a potent lymphangiogenic activity on LN-LECs at nanomolar concentrations (10 ng/mL), suggesting that the p17 biological activity we observe in vitro may likely occur in the HIV-1-infected host. It is worth noting that several authors demonstrated the binding of p17 to heparan sulfate proteoglycans. 29, 30 Such interaction, as already demonstrated for many heparin-binding chemokines, 31 may allow a better presentation of p17 to CXCR1 and CXCR2 setting up synergistic and cooperative interactions leading to increased concentrations of the viral protein at the LN-LEC surface.
CXCR1 and CXCR2 use different signal transduction cascades that result in the activation of small G proteins and evoke pleiotropic responses in target cells. Our previous results obtained in human ECs have shown that both receptors are involved in promoting angiogenic activity, defining Akt and ERK as the signaling molecules responsible for p17 proangiogenic function, whereas PI3K activity was identified as a key intermediate in coupling CXCR1 and CXCR2 to Akt and ERK signaling. 21 Here, we show that p17 requires both CXCR1 and CXCR2 to exert its lymphangiogenic activity and that signaling events similar to those observed in p17-treated ECs are evoked in LN-LECs after p17 stimulation. As in p17-stimulated ECs, p17 treatment of LN-LECs gave rise to the activation of PI3K/ Akt and MEK/ERK1/2 signaling pathways, because specific inhibitors of both pathways completely blocked p17-induced capillary-like structure formation. All these results confirm that both pathways are required and may function cooperatively in driving p17-induced capillary-like structure formation.
ET-1 is a proangiogenic factor. 32, 33 Members of the ET-1 axis are frequently overexpressed in many solid tumors, 34, 35 and their expression has been correlated with increased lymphatic dissemination. 27 In a recent article, we described the capability of ET-1 to promote lymphangiogenesis and migration of LECs through a mechanism mediated by ET B R-ET-1driven effects being completely abrogated in the presence of the specific ET B R antagonist BQ788. 27 Therefore, the finding that ET-1 was increased in the supernatant of LN-LECs after p17 stimulation led us to hypothesize a role of the ET-1/ET B R axis in p17-driven lymphangiogenic activity of LN-LECs. Indeed, the presence of the ET B R specific antagonist BQ788 was able to downmodulate p17-induced capillary-like structure formation. Furthermore, we demonstrated that in the Matrigel plug neovascularization assay, p17 promotes per se the outgrowth of lymphatic vessels in vivo. Data obtained support the hypothesis that p17 stimulates lymphangiogenesis directly and also indirectly via the ET-1/ET B R axis. It is worth noting that ET-1/ET B R interaction leading to lymphangiogenesis is dependent on activation of ERK1/2 and Akt. 27 Thus, the signaling cascade involving activation of the Akt-dependent ERK signaling pathway triggered within LN-LECs by p17 interaction with CXCR1 and CXCR2 is likely to be enforced and sustained by a secondary ET-1/ET B R interaction, which may contribute to exert a stronger and more prolonged p17 lymphangiogenic activity.
Previous data have shown that ET-1-induced lymphangiogenesis is mediated by the release of other lymphangiogenic regulators including VEGF-A and VEGF-C. 27 Here, we show that p17-treated LN-LECs do not release these molecules in the supernatant, suggesting that VEGF-A and VEGF-C are not involved in the p17-induced lymphangiogenic mechanism. However, the release and quick consumption of these selective lymphangiogenic factors by LN-LECs cannot be completely ruled out and require further investigation.
In view of the expression and persistence even during successful HAART of p17 in lymph nodes of HIV-1-seropositive patients, 14 together with the recent gene expression profile identifying ET-1 as one of the significant genes in LECs isolated from metastatic lymph nodes, 36 the present results raise the possibility that p17, per se and by activating the ET-1/ ET B R axis, may contribute to tumor progression in lymph nodes of HIV-1-seropositive patients by promoting potent lymphangiogenic signaling.
Chronic inflammation because of the presence of activated monocytes and macrophages in lymph nodes is known to trigger and sustain aberrant lymphangiogenesis 37 and to induce the development of genomic abnormalities and tumor progression. 38 Complexity of p17 activities includes also its capability to trigger the production of proinflammatory cytokines and chemokines from different immune cells, including monocytes/ macrophages. 15, 17 This could have a particular relevance in lymphoid organs where it may recruit activated monocytes through CXCR1 engagement 19 and induce the release of inflammatory and angiogenic molecules in situ, including ET-1. 17, 39 Although pharmacological inhibition of lymphangiogenesis may be clinically relevant in ARLs, the number of available drugs is limited. 36 In this context, the present study indicates that molecules targeting the p17/CXCR1 and CXCR2 axis, as well as the ET-1/ET B R axis, are potential candidates in the treatment of lymphangiogenesis associated with ARLs.
ARLs comprise a narrow spectrum of histological types consisting almost exclusively of aggressive B-cell tumors derived from either germinal centers or postgerminal centers. HIV-1 creates a milieu of combined immune suppression and chronic antigenic stimulation in lymph nodes. 40 This environment with dysregulated cytokine/chemokine release and B-cell hyperstimulation 41 along with the presence of concomitant infection (eg, Epstein-Barr virus, human herpesvirus type 8, cytomegalovirus) may promote a permissive environment for HIV-1-induced B-cell expansion and impaired immune surveillance, culminating in lympho-proliferative disorders. 42 Up until now, the molecular mechanisms responsible for B-cell transformation associated with ARLs have not been elucidated. However, in this respect it is worth noting that recent data have highlighted a role for p17 variants in promoting B-cell growth and malignant transformation in vitro. 18 This was related to a p17 variant-induced dysregulation of the PI3K/Akt signal transduction pathway, a hallmark of different types of malignancies known to play a central role in tumorigenesis and cancer progression. 43, 44 Collectively, all these evidences corroborate the hypothesis that p17 may play a key role in producing a microenvironment that fosters lymphoma development, progression, and metastasis. The significant importance of blocking the biological activity of p17 is becoming apparent. 45 This may be achieved by using p17-specific drugs 46 or by specific vaccines aimed to generate a neutralizing p17 antibody response. 47 The knowledge that p17 triggers common pathways of lymphangiogenesis and angiogenesis, which represent important routes of metastasis, may offer new opportunities to identify novel treatment strategies in preventing and combating ARLs.
